285 related articles for article (PubMed ID: 19772289)
41. Differential androgen and estrogen substrates specificity in the mouse and primates type 12 17beta-hydroxysteroid dehydrogenase.
Blanchard PG; Luu-The V
J Endocrinol; 2007 Aug; 194(2):449-55. PubMed ID: 17641292
[TBL] [Abstract][Full Text] [Related]
42. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
[TBL] [Abstract][Full Text] [Related]
44. Simultaneous determination of testosterone, 5alpha-androstan-17beta-ol-3-one, 5alpha-androstane-3alpha,17beta-diol and 5alpha-androstane-3beta,17beta-diol in plasma of adult male rabbits by radioimmunoassay(1).
Schanbacher BD; Ewing LL
Endocrinology; 1975 Oct; 97(4):787-92. PubMed ID: 1193006
[TBL] [Abstract][Full Text] [Related]
45. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
[TBL] [Abstract][Full Text] [Related]
46. Rapid and intensive conversion of 5alpha-androstane-3alpha, 17beta-diol into 5alpha-dihydrotestosterone in the male rat anterior pituitary: in vivo and in vitro studies.
Pilven A; Thieulant ML; Ducouret B; Sampérez S; Jouan P
Steroids; 1976 Sep; 28(3):349-58. PubMed ID: 982493
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and steroid sulphatase inhibitory activity of C19- and C21-steroidal derivatives bearing a benzyl-inhibiting group.
Ciobanu LC; Boivin RP; Luu-The V; Poirier D
Eur J Med Chem; 2001; 36(7-8):659-71. PubMed ID: 11600235
[TBL] [Abstract][Full Text] [Related]
48. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
49. Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.
Kenmogne LC; Roy J; Maltais R; Rouleau M; Neveu B; Pouliot F; Poirier D
PLoS One; 2017; 12(2):e0171871. PubMed ID: 28182747
[TBL] [Abstract][Full Text] [Related]
50. Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase.
He XY; Yang YZ; Peehl DM; Lauderdale A; Schulz H; Yang SY
J Steroid Biochem Mol Biol; 2003 Nov; 87(2-3):191-8. PubMed ID: 14672739
[TBL] [Abstract][Full Text] [Related]
51. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
53. Synthesis of substituted 15β-alkoxy estrone derivatives and their cofactor-dependent inhibitory effect on 17β-HSD1.
Herman BE; Kiss A; Wölfling J; Mernyák E; Szécsi M; Schneider G
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1271-1286. PubMed ID: 31307240
[TBL] [Abstract][Full Text] [Related]
54. Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer.
Ishizaki F; Nishiyama T; Kawasaki T; Miyashiro Y; Hara N; Takizawa I; Naito M; Takahashi K
Sci Rep; 2013; 3():1528. PubMed ID: 23524847
[TBL] [Abstract][Full Text] [Related]
55. 6-Hydroxybenzothiophene ketones: potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) owing to favorable molecule geometry and conformational preorganization.
Miralinaghi P; Schmitt C; Hartmann RW; Frotscher M; Engel M
ChemMedChem; 2014 Oct; 9(10):2294-308. PubMed ID: 25044709
[TBL] [Abstract][Full Text] [Related]
56. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
[TBL] [Abstract][Full Text] [Related]
57. 5Alpha-androstane-3beta,7alpha,17beta-triol and 5alpha-androstane-3beta,7beta,17beta-triol as substrates for the human 11beta-hydroxysteroid dehydrogenase type 1.
Hennebert O; Le Mée S; Pernelle C; Morfin R
Steroids; 2007 Nov; 72(13):855-64. PubMed ID: 17825335
[TBL] [Abstract][Full Text] [Related]
58. Impact of androstane A- and D-ring inversion on 17β-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability.
Cortés-Benítez F; Roy J; Maltais R; Poirier D
Bioorg Med Chem; 2017 Apr; 25(7):2065-2073. PubMed ID: 28254377
[TBL] [Abstract][Full Text] [Related]
59. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
60. Mutual regulations and breast cancer cell control by steroidogenic enzymes: Dual sex-hormone receptor modulation upon 17β-HSD7 inhibition.
Sang X; Han H; Li T; Lin SX
J Steroid Biochem Mol Biol; 2019 Oct; 193():105411. PubMed ID: 31207361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
